目前的研究旨在通过开发一种先进的长期药物输送系统来解决传统癌症治疗的局限性，该系统使用生物相容性的玫瑰红（RB）负载的聚乙烯醇（PVA）基质并融入3D打印的聚己内酯（PCL）和聚乳酸中。 PLA）植入物。抗癌药物RB的高溶解度和低亲脂性需要频繁且痛苦地向肿瘤部位给药，限制了其临床应用。在这项研究中，RB被封装在PVA（RB@PVA）基质中，以克服这些挑战，并在设计用于植入肿瘤部位附近的可生物降解植入物中实现局部持续药物释放系统。 RB@PVA 基质的 RB 负载效率为 77.34±1.53%，并在 30 分钟内完全释放 RB。然而，当集成到植入物中时，该系统在 90 天内提供了 75.84±8.75% 的持续 RB 释放。对 PC-3 前列腺癌细胞的细胞毒性测定表明，RB@PVA 的 IC50 值为 1.19 µM，而游离 RB 的 IC50 值为 2.49 µM，可有效抑制癌细胞增殖。这种创新的药物输送系统将聚合物基质纳入可植入装置中，代表了水溶性药物缓释方面的重大进步。它有望减少给药频率，从而提高患者的依从性，并将实验研究转化为实际的治疗应用。© 2024。作者。

The current investigation aims to address the limitations of conventional cancer therapy by developing an advanced, long-term drug delivery system using biocompatible Rose Bengal (RB)-loaded polyvinyl alcohol (PVA) matrices incorporated into 3D printed polycaprolactone (PCL) and polylactic acid (PLA) implants. The anticancer drug RB's high solubility and low lipophilicity require frequent and painful administration to the tumour site, limiting its clinical application. In this study, RB was encapsulated in a PVA (RB@PVA) matrix to overcome these challenges and achieve a localised and sustained drug release system within a biodegradable implant designed to be implanted near the tumour site. The RB@PVA matrix demonstrated an RB loading efficiency of 77.34 ± 1.53%, with complete RB release within 30 min. However, when integrated into implants, the system provided a sustained RB release of 75.84 ± 8.75% over 90 days. Cytotoxicity assays on PC-3 prostate cancer cells indicated an IC50 value of 1.19 µM for RB@PVA compared to 2.49 µM for free RB, effectively inhibiting cancer cell proliferation. This innovative drug delivery system, which incorporates a polymer matrix within an implantable device, represents a significant advancement in the sustained release of hydrosoluble drugs. It holds promise for reducing the frequency of drug administration, thereby improving patient compliance and translating experimental research into practical therapeutic applications.© 2024. The Author(s).